Eli Lilly set to acquire Kelonia Therapeutics in $7 billion genomic medicine play

Eli Lilly and Kelonia Therapeutics have announced a definitive agreement for Lilly to acquire the clinical stage biotechnology firm. The deal centers on Kelonia’s proprietary in vivo gene placement system, known as iGPS, which utilizes engineered lentiviral particles to modify T cells directly inside a patient’s body. This approach allows the body to generate its own CAR T cell therapies, potentially bypassing the intensive manufacturing and chemotherapy requirements of traditional methods.

Clinical Validation and the Lead Program

The acquisition is headlined by KLN 1010, a one time intravenous therapy for multiple myeloma. By targeting the BCMA protein, this candidate seeks to provide a transformative alternative to existing treatments. Initial clinical data presented at the 2025 American Society of Hematology Annual Meeting provided early validation for the platform, showing both efficacy and a promising safety profile.

Leadership Insights

Jacob Van Naarden, executive vice president and president of Lilly Oncology, highlighted the strategic importance of the platform:

“Autologous CAR-T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them. Kelonia’s in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format. The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform. We look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need and recognize the full potential of their platform in other conditions where patients may benefit.”

Kevin Friedman, Ph.D., chief executive officer of Kelonia, noted the broader implications for the industry:

“Kelonia’s leadership in advancing the immense promise of in vivo cell therapy is unmatched, extending its reach and impact beyond the traditional boundaries of personalized medicine. We have demonstrated the ability to achieve deep multiple myeloma remissions with significantly reduced complexity and cost relative to ex vivo CAR T-cell approaches. In combination with Lilly’s strengths, our in vivo iGPS platform is positioned to broaden the reach of cell therapy beyond the current CAR-T landscape in hematologic malignancies and to transform treatment across a far wider range of cancers and other serious diseases. It’s been a privilege continuing the journey started by Michael Birnbaum and the Venrock team. I am deeply grateful to our employees, partners, and investigators, and most importantly, the patients who make this progress possible.”

Transaction Details

Lilly will acquire Kelonia for a total value of up to $7.00 billion. This includes an immediate upfront payment of $3.25 billion, with the remaining $3.75 billion tied to the successful achievement of clinical, regulatory, and commercial milestones. The deal is expected to close in the second half of 2026, subject to standard regulatory approvals.

---

---

Related Topics and Keywords

Eli Lilly, Eli Lilly and Co, kelonia, lilly pharma